Increased immune cell infiltration into tumors is associated with improved patient survival
and predicts response to immune therapies. Thus, identification of factors that determine the …

Tumor-associated tertiary lymphoid structures (TA-TLS) are associated with enhanced
patient survival and responsiveness to cancer therapies, but the mechanisms underlying …

Water-in-oil emulsion incomplete Freund's adjuvant (IFA) has been used as an adjuvant in
preventive and therapeutic vaccines since its development. New generation, highly purified …

The development of vaccines against cancer has driven significant advancements in tumor
immunology, leading to a better understanding of the immune response against cancer …

Background Cancer vaccines require adjuvants to induce effective immune responses;
however, there is no consensus on optimal adjuvants. We hypothesized that toll-like …

Objective: To understand role of barrier molecules in melanomas. Background: We have
reported poor patient survival and low immune infiltration of melanomas that overexpress a …

Background Immunogenicity of cancer vaccines is impacted by adjuvants and schedule, but
systematic assessments of their effects have not been performed. Montanide ISA-51, an …

CD8+ T-cell infiltration and effector activity in tumors are correlated with better overall
survival of patients, suggesting that the ability of T cells to enter and remain in contact with …

The strength and durability of systemic anti-tumor immune responses induced by cancer
vaccines depends on adjuvants to support an immunogenic vaccine site microenvironment …

ABSTRACT Integrins α1β1 (CD49a), α2β1 (CD49b) and αEβ7 (CD103) mediate retention of
lymphocytes in peripheral tissues, and their expression is upregulated on tumor infiltrating …